David F. McDermott

1.2k citations
12 papers · 915 indexed · 1 hit paper · h-index 8

David F. McDermott

11 papers receiving 895 citations

Hit Papers

Randomized Phase III Trial of High-Dose Interleukin-2 Ver...5982004202620112018100200300400500

Peers

David F. McDermott
Comparison fields: 5 of 59
  • Cancer Research 294
  • Pulmonary and Respiratory Medicine 572
  • Oncology 441
  • Molecular Biology 510
  • Immunology 153
Replace Motokazu Suyama with:
Motokazu Suyama Japan
Marta Bonotto Italy
Mikhail Shtivelband United States
Suman Redhu United States
Olga Valota Italy
Edward Arrowsmith United States
S. Gail Eckhardt United States
Elena Poddubskaya Russia
Erin Macrae United States
David F. McDermott relative to Motokazu Suyama Japan Motokazu Suyama's profile →
Citations per field
00.5×4.6×
Motokazu Suyama · 1×
Citations per year

Countries citing papers authored by David F. McDermott

Since Specialization
Citations

This map shows the geographic impact of David F. McDermott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David F. McDermott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David F. McDermott more than expected).

Fields of papers citing papers by David F. McDermott

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David F. McDermott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David F. McDermott. The network helps show where David F. McDermott may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David F. McDermott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David F. McDermott Line = papers co-authored together David F. McDermott links everyone, so they are left out of the graph.

All Works

12 of 12 papers shown
#Work
1 20250
2 20243
3 20197
4 20199
5 20182
6 20181
7 201712
8 201033
9 200824
10 200828
11 2006198
12
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinomabreakdown →
2004598

About David F. McDermott

David F. McDermott is a scholar working on Pulmonary and Respiratory Medicine, Nephrology and Oncology, having authored 12 papers that have together received 915 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (10 papers), Bladder and Urothelial Cancer Treatments (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Renal and related cancers (2 papers), Cancer Genomics and Diagnostics (2 papers), Renal Diseases and Glomerulopathies (2 papers), Sarcoma Diagnosis and Treatment (1 paper) and Economic and Financial Impacts of Cancer (1 paper). The work is most often cited by research in Cancer Research (294 citations), Pulmonary and Respiratory Medicine (572 citations) and Oncology (441 citations). David F. McDermott has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Michael B. Atkins, Jeffrey A. Sosman, Janice P. Dutcher, Marc S. Ernstoff, John W. Smith, Walter J. Urba, Christopher Tretter, Jared Gollob, Geoffrey R. Weiss and James W. Mier. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026